Media Invite – ResearchNB Funding Announcement in Cancer Research
MONCTON, NB, November 8, 2024 /CNW/ – An important announcement regarding cancer research funding is set to unfold in New Brunswick, and members of the media are cordially invited to attend this significant event. This announcement marks a pivotal moment for cancer research initiatives in the region, with the unveiling of new support for innovative research projects.
BeiGene Canada, the Canadian arm of the global biotechnology leader BeiGene, is poised to reveal its commitment to advancing cancer research. The company will announce its support for two groundbreaking cancer research projects under the auspices of the BeiGene Canada Fund for Research and Innovation. This esteemed research fund is dedicated to fostering cutting-edge research and innovation aimed at addressing unmet needs and enhancing cancer care across Canada.
The much-anticipated announcement will take place at the Delta Moncton Beausejour, forming a highlight of ResearchNB’s annual Health Research Symposium. This symposium is a prestigious event that showcases ongoing health research efforts within New Brunswick, providing a platform for highlighting the province’s contributions to global scientific advancements.
Spotlight on Distinguished Researchers
Among the notable recipients of funding are Dr. Rodney J. Ouellette, a revered Senior Researcher and the Founder of the Atlantic Cancer Research Institute, and Dr. Stephen M. Lewis, the Scientific Director of the same esteemed institute. Their collective expertise and pioneering research endeavors are poised to benefit significantly from this new influx of support, further propelling advances in cancer treatment and patient care.
Dr. Rodney J. Ouellette: As a leading figure in the field of cancer research, Dr. Ouellette’s contributions have been instrumental in advancing our understanding of cancer biology. His leadership at the Atlantic Cancer Research Institute has been pivotal in driving forward research that seeks to uncover innovative therapeutic approaches.
Dr. Stephen M. Lewis: With a rich background in scientific exploration, Dr. Lewis has played a crucial role in steering the institute’s research objectives. His dedication to scientific excellence and innovation continues to inspire new avenues for cancer research.
Keynote Speakers and Participants
The announcement will also feature key remarks from Peter Brenders, the General Manager of BeiGene Canada, who will elaborate on the company’s vision and commitment to improving cancer care through impactful research collaborations.
This gathering provides an invaluable opportunity for media representatives to capture insights from leading experts and stakeholders in the field of cancer research. Attendees will gain a firsthand understanding of the transformative research initiatives supported by the BeiGene Canada Fund for Research and Innovation.
The symposium itself serves as a vital conduit for fostering collaboration and knowledge exchange among researchers, healthcare professionals, and industry leaders. It is a testament to the dynamic research landscape in New Brunswick and its pivotal role in driving forward health innovations.
Event Details:
Venue: Delta Moncton Beausejour
Part of: ResearchNB’s Annual Health Research Symposium
Media personnel interested in attending the event or those wishing to arrange interviews with the key speakers and researchers are encouraged to RSVP. This ensures seamless coordination and facilitation of media coverage.
For RSVP and interview scheduling, please contact the event organizers. This exclusive gathering promises to be a landmark moment in the realm of cancer research, highlighting the cooperative efforts that are pivotal in transforming cancer care through scientific innovation.
This event is a testament to the ongoing collaborative efforts to tackle one of the most pressing health challenges of our time. It underscores the commitment of BeiGene Canada and the Atlantic Cancer Research Institute to pioneering research that has the potential to improve patient outcomes and quality of life for individuals battling cancer.
